{"url_path":"/sec/vyne/8-k/2026-07-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-085235-index.html","accession_number":"0001104659-26-085235","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-085235-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":1085,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n \nDescription\n\n[99.1](tm2620874d1_ex99-1.htm)\n \n[Press\nRelease issued by VYNE Therapeutics Inc. on July 21, 2026, furnished herewith.](tm2620874d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n**Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains\nforward-looking statements (including within the meaning of the Exchange Act, and Section 27A of the Securities Act) concerning VYNE,\nYarrow, the proposed transactions and other matters. These forward-looking statements include express or implied statements relating to\nthe structure, timing and completion of the proposed Merger; the expected Reverse Stock Split, including the timing thereof; and other\nstatements that are not historical fact. The words “anticipate,” “believe,” “contemplate,” “continue,”\n“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”\n“possible,” “potential,” “predict,” “project,” “should,” “will,”\n“would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking\nstatements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are\nbased on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future\ndevelopments affecting VYNE, Yarrow or the proposed transactions will be those that have been anticipated.\n\n \n\nThe forward-looking statements contained in this\nCurrent Report on Form 8-K are based on current expectations and beliefs concerning future developments and their potential effects\nand therefore are subject to other risks and uncertainties. These risks and uncertainties include, but are not limited to, risks associated\nwith the possible failure to satisfy the conditions to the closing or consummation of the Merger; risks associated with the uncertainty\nas to the timing of the consummation of the Merger and the ability of each of VYNE and Yarrow to consummate the transactions contemplated\nby the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger\nprior to the closing or consummation of the Merger; risks associated with the possible failure to realize certain anticipated benefits\nof the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on the combined\ncompany’s business relationships, operating results and business generally; risks associated with the combined company’s ability\nto manage expenses and unanticipated spending and costs that could reduce the combined company’s cash resources; risks related to\nthe combined company’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements;\nrisks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates\nor its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company or any of its directors\nor officers related to the Merger Agreement or the transactions contemplated thereby; the ability of the combined company to obtain, maintain\nand protect its intellectual property rights, in particular those related to its product candidates; the combined company’s ability\nto advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future\nclinical trials; the combined company’s ability to replicate in later clinical trials positive results found in preclinical studies\nand early-stage clinical trials of its product candidates; the combined company’s ability to realize the anticipated benefits of\nits research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or\ndevelopments and the combined company’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other\nregulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in\nexpected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes\nto business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; changes\nin the net cash of VYNE and the per share dividend amount, each as determined in accordance with the terms of the Merger Agreement, relative\nto the currently estimated amounts; and those risks and uncertainties and other factors more fully described in filings with the SEC,\nincluding reports filed on Form 10-K, 10-Q and 8-K and in other filings made by VYNE with the SEC from time to time and available\nat www.sec.gov. These forward-looking statements are based on current expectations, and with regard to the proposed transactions, are\nbased on VYNE’s current expectations, estimates and projections about the expected date of closing of the proposed Merger and the\npotential benefits thereof, its business and industry, management’s beliefs and certain assumptions made by VYNE, all of which are\nsubject to change. Such forward-looking statements are made as of the date of this Current Report on Form 8-K, and the parties undertake\nno obligation to update such statements to reflect subsequent events or circumstances, except as otherwise required by securities and\nother applicable law.\n\n \n\n \n\n \n\n \n\n**No Offer or Solicitation**\n\n \n\nThis Current Report on Form 8-K is not intended\nto and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the\nproposed transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase\nor subscribe for any securities pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer\nof securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus\nmeeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by the relevant\nregulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where\nto do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including\nwithout limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national\nsecurities exchange, of any such jurisdiction.\n\n \n\nNEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION\nHAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K IS TRUTHFUL OR COMPLETE.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**VYNE THERAPEUTICS INC.**\n\n \n \n\nDate: July 21, 2026\n/s/ Mutya Harsch\n\n \nMutya Harsch\n\n \nChief Legal Officer and General Counsel"}